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Measurement of Immunoreactive lnterleukin-1 (3 from Human 
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Tumor Necrosis Factor1
S t e f a n  E n d r e s , R e z a  G h o r b a n i , G e r h a r d  L o n n e m a n n ,
Jos W. M. v a n  d e r  M e e r ,  a n d  C h a r l e s  A. D i n a r e l l o 2
Department o f  Medicine, Division o f  Geographic Medicine and Infectious Diseases, New England 
Medical Center Hospitals and Tufts University School o f  Medicine, 750 Washington Street,
Boston, Massachusetts 02111
N u m ero u s  studies have reported  altered levels o f  in vitro p roduction  o f  the cy tok ines  
in ter leukin -1 (IL-1) and tu m o r  necrosis  factor (TN F) from blood leukocytes  in various 
hum an disease s tates.  Most o f  these  studies have used bioassays which are vulnerable  to 
inhibitors produced  by these cells. Fur therm ore  in vitro cy tokine  production  is often 
assessed  on a single occasion .  The  present s tudy was designed to s tandard ize  stimulation 
condit ions  for in vitro IL -1 (3 production  and to em ploy  a competi t ive  rad io im m unoassay  
(RIA) to dem ons tra te  reproducibil i ty  and long-term variation o f  in vitro cy tokine  p ro ­
duction in a cohort  of  healthy human subjects.  We also exam ined  relative am ou n ts  o f  
im m unoreac t ive  IL-1(3, I L - l a ,  and T N F  induced by the stimuli endo tox in ,  p h y to h em ag ­
glutinin. o r  Staphylococcus epidermidis. We show that the RIA can reliably de tec t  IL-1 (3 
p roduced  from m ononuc lea r  cells in concen tra t ions  as low as 115 pg/ml. Lysing cells by 
repea ted  f reeze- thaw ing  yields maximal recovery  o f  total ( i .e . ,  sec re ted  plus cell- 
associa ted)  im m unoreac tive  IL -1 (3, when com pared  to ex trac tion  with the de te rgen t  
C H A P S  or  addition of  p ro tease  inhibitors. Repeated  m easurem en t  o f  in vitro cy tokine  
production  on different days  within 1 week show s good reproducibil i ty  for a given 
individual and a given stimulus (variation coefficient 20 to 30%). O ver  a long time period 
(6 months) in vitro cy tokine  production is stable in some individuals but changes  c o n ­
siderably in o thers .  The  soluble stimulus endotoxin  induces twofold more I L - l a  than 
I L - lp  o r  T N F ;  in con tras t  the phagocytic  stimulus heat-killed S. epidermidis induces 
fourfold more IL -1 (3 and T N F  than I L - l a .  This distinct pattern  o f  cy tokine  response  
indicates differential stimulation of  the m ononuc lea r  cells by different stimuli. The re­
sults form the basis for studying in vitro cy tokine  production  in different hum an disease
states.  © 1988 Academic Press, Inc.
INTRODUCTION
Interleukin-ip (IL-lp), interleukin-la (IL -la) ,  and tumor necrosis factor (TNF) 
are polypeptides produced by monocytes and other cells. These cytokines par­
ticipate at several levels of the immune response and mediate many of the acute 
phase changes in response to injury, infection, immunologic, or malignant disease 
( 1 , 2).
Numerous studies have investigated whether the amount of in vitro IL -1 or T N F
1 Suppor ted  by N1H Grant  Al 15614 and by Cistron Biotechnology Inc.,  Pine Brook, NJ. S .E .  is 
recipient o f  Grant  En 169/1 from the Deutsche Forschungsgem einschaft .
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production from mononuclear cells is altered in various human disease states. 
Decreased IL-1 production has been reported in patients with systemic lupus 
erythematosus (3, 4), pemphigus vulgaris (5), scleroderma (6), malnutrition (7, 8), 
fatal sepsis (9), as well as in patients with duodenal ulcer on cimetidine therapy
(10). In vitro production of IL-1 appears to be increased in patients with rheuma­
toid arthritis (11, 12), idiopathic osteoporosis (13), chronic liver disease (14), 
major burns (15), Hodgkin’s disease (16), or tuberculosis (17). For some disease 
states a ‘‘normal level" of in vitro IL-1 production when compared to healthy 
controls has been reported. These include ankylosing spondylitis (18), asthma 
(19), multiple sclerosis (20), chronic lymphocytosis (21), graft-versus-host disease 
after allogenic bone marrow transplantation (22), and leprosy (23). Alterations of 
in vitro IL-1 production in patients with human immunodeficiency virus infection 
have been reported to differ dependent on stage of disease; increased levels of 
production were found in patients with generalized lym phadenopathy (24), 
whereas production appeared to be decreased (25) or unchanged (26, 27) in pa­
tients with fully developed acquired immunodeficiency syndrome. Increased in 
vitro production of T N F  has been reported in some cancer patients (28).
The above-described studies primarily used bioassays to determine the amount 
of cytokine production following stimulation of blood mononuclear cells. Further­
more, cytokine production was determined for a given individual on a single 
occasion most often to a single stimulus, usually endotoxin.
The present study pursued the following goals: (i) to define the optimal condi­
tions for in vitro cytokine synthesis by human mononuclear cells (MNC); (ii) to 
optimize recovery of immunoreactive IL-1 p from MNC; (iii) to employ a sensitive 
and specific radioimmunoassay (RIA) that is less vulnerable to inhibitory and 
potentiating factors of bioassays; and (iv) to determine the reproducibility of in 
vitro IL-1 and T N F  production for a given individual at different time points 
(intrasubject variation). Moreover we compared the relative amount of immuno­
reactive IL - ip ,  IL - la ,  and T N F produced by MNC in response to different stim­
uli. These studies form the basis for methods to quantitate IL -1 (3, IL - la ,  and T N F 
production from human MNC in vitro in order to assess elevated or decreased 
production as part of a disease process.
MATERIALS AND METHODS
Preparation o f  Anti-IL-1 p Antiserum
New Zealand white rabbits (Pine Acres, Burlington, VT) were immunized with 
100 fxg recombinant human interleukin-1(3 (hrIL-ip) in complete F reund’s adju­
vant by intradermal injections as previously described (29). Human rIL -ip  was 
obtained from Cistron (Pine Brook, NJ) and is the 17.5 kDa protein representing 
the carboxy-terminus of the IL -ip  precursor molecule. It is >99% pure by SD S- 
polyacrylamide gel electrophoresis, has a specific activity of 2 x 10h U/mg, and 
has alanine N-terminus homogeneity (position 112). At monthly intervals the rab­
bits received booster immunizations by intramuscular injection of 25 |xg h rIL -ip  
in incomplete F reund’s adjuvant. After 29 weeks the rabbits were bled, and the 
unfractionated serum was pooled and used as anti-IL-lp antiserum.
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Radiolabeling o f  hrIL-lfi
Human rIL -ip  was labeled as previously described (30) using the chloramine-T 
method (31). Ten micrograms of h rIL -lp  (1 fjig/fil, kindly provided by Dr. Alan 
Shaw, Glaxo Institute of Molecular Biology, Geneva, Switzerland) was mixed 
with 0.5 mCi N a ,2SI (100 mCi/ml, New England Nuclear, Boston, MA) and was 
added to 10 |jlI of 0.5 M  sodium phosphate buffer (pH 7.4) in a 500-|xl polypro­
pylene tube. Next, 10 fxg chloramine-T (Sigma Chemical Co., St Louis, MO; 2.5 
mg/ml in 0.25 M  sodium phosphate buffer, pH 7.4) was added and mixed by 
pipetting for exactly 10 sec. The reaction was terminated by adding 20 fjil of the 
reducing agent sodium metabisulfite (Sigma; 5 mg/ml in 0.25 M  sodium phosphate 
buffer, pH 7.4). Finally 300 fxl of bovine serum albumin (BSA) buffer containing 
0.01 M  phosphate-buffered saline, 0.25% BSA (Sigma), and 0.05% sodium azide 
was added.
The radiolabeled materia! was immediately chromatographed on a Sephadex 
G-50 (fine) (Pharmacia, Piscataway, NJ) column (0.8 x 30 cm) which separated 
the radiolabeled protein from the free l25I. BSA buffer was used to equilibrate the 
column. Forty fractions (0.5 ml) were collected. The radioactivity of 100 |xl of a 
1:100 dilution of these fractions was determined in a gamma counter. One hundred 
microliters of a 1:100 dilution of each fraction was incubated with a 1:100 dilution 
of the an ti- lL -lp  antiserum for 18 hr at room temperature, and then was precip­
itated by adding 500 fil of 6% (w/v) polyethylene glycol 8000 (PEG; Fisher Sci­
entific Company, Fair Lawn, NJ) and 2% sheep anti-rabbit IgG (Cambridge Med­
ical Diagnostics, Billerica, MA). After centrifugation (15 min, 1500g) and decant­
ing, the precipitated radioactivity was counted in a gamma counter. Those 
fractions in which anti-hrlL-lap  antiserum precipitated more than 85% of the total 
counts were pooled and used as the tracer in the RIA. The incorporated radioac­
tivity in this pool was derived by multiplying the total radioactivity used in the 
labeling reaction by the proportion of bound iodine (area under peak of precip- 
itable iodine) as the percentage of total iodine (combined area of peaks for free and 
precipitable iodine). The specific activity of the pool was calculated by dividing 
the incorporated activity by the amount of protein used in the labeling reaction. It 
ranged between 25 and 40 |xCi/|xg in several iodinations. This is similar to the 
specific activity for radioiodinated IL-10 previously reported (30).
T he  h o m o g e n e i ty  o f  the  1251 - h r I L - 1 p w as d e m o n s t r a t e d  by S D S -  
polyacrylamide gel electrophoresis (32) and autoradiography. A single band at 17 
kDa was observed. l25I-hrIL-ip  was biologically active as determined by a comi- 
togenic assay using the murine-cloned T cell line D.10G4.1 (29).
Titration o f  the Anti-IL-1$ Antiserum
[ l25I]hrIL-lp  (10,000 cpm) in 100 (jlI BSA buffer was incubated with serial 
twofold dilutions of the anti-IL-ip antiserum for 18 hr at room temperature and
then precipitated with 500 |xl of 6% PEG and 2% sheep anti-rabbit IgG (Fig. 1).
* 1 ^  ^The dilution of anti-1 L -1 p antiserum that precipitates about 35% of I-hrIL-ip
(i.e., 1:6400) was chosen for use in the RIA.
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F ig .  I. Titration o f  anti IL - ip  antiserum. Serial twofold dilutions o f  anti IL-I(i an tiserum  were 
incubated  overnight with l25I-hrIL-l(3 and precipita ted with sheep anti-rabbit IgG in PEG. Precipitated
7  activity is exp ressed  as the percentage o f  total counts .  The dilution (1:6400) that precipita tes  about 
35% o f  i :s I-hrIL-l(3 (indicated by the horizontal line) was chosen  for use in the RIA.
Separation o f  Bound from Free ]2S I-hrIL-1 ft
 ^ I ^  S • •To separate bound from free I-h rlL -1 (3, antigen-antibody complexes were 
precipitated with a sheep anti-rabbit IgG antiserum. Precipitate formation was 
enhanced by adding normal rabbit serum and polyethylene glycol. To optimize 
precipitation conditions, 10,000 cpm of 12SI-hrIL-1 (3 in 100 jxl BSA buffer, 100 |xl 
of anti-IL-1 p antiserum, and 300 [x\ of either 1:300 or 1:600 dilution of NRS were 
incubated overnight. Bound label was precipitated by adding 500 jjlI of sheep 
anti-rabbit IgG antiserum at serial dilutions in 6% or 10% (w/v) PEG amounting to 
final concentrations of 2.7 or 4.5% (w/v) PEG, respectively (Fig. 2). Maximal 
precipitation was achieved with a 1:600 dilution of NRS and a 1:50 dilution of sheep 
anti-rabbit IgG in 6% PEG. These conditions were subsequently used for the RIA. 
They differ from the previously described procedure (30) by the addition of 300 \x\
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F ig .  2. Dose response  for sheep  anti-rabbit IgG antiserum. One hundred microliters of  l2<iI-hrIL-l(3, 
100 fil o f  1:6400 diluted anti IL-1 (3 antiserum  and 300 |jl1 o f  e ither  a 1:600 or  a 1:300 dilution o f  NRS 
were  incubated  overnight.  Bound label was precipitated by adding 500 fxl o f  sheep anti-rabbit IgG 
an tiserum  at serial dilutions in 6 o r  10% (w/v) PEG (final dilutions (2.7 or  4.8%, respectively).
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RIA buffer as ‘‘carrier volume" at Day 1, and by lower final concentrations of 
sheep anti-rabbit IgG antiserum (0.9 instead of 2%) and of PEG (2.7 instead of 
4.8% w/v).
Radioimmunoassay fo r  IL-I (3
Known standards and samples were assayed in duplicate or triplicate in 10 x 
75-mm polystyrene tubes (Stockwell Scientific, Walnut, CA). In every assay, nine 
standards of h r lL -1 (3 (10,000, 5000, 2500, 1250, 625, 313, 157, 79, 40, and zero 
pg/ml) diluted in BSA buffer were employed. On Day 1, 100 fxl of the anti-hrIL-1 (3 
antiserum (diluted 1:6400) was added to 100 |xl of the standards or to 100 ^1 of the 
samples. To one pair of tubes 100 [¿I of BSA buffer was added instead of 
an ti-IL-ip  antiserum in order to determine nonspecific binding (NSB) of the 
tracer. BSA buffer (300 fxl) containing a 1:600 dilution of heat-inactivated normal 
rabbit serum was added to each tube. The tubes were vortexed and incubated at 
room temperature overnight. On Day 2, 100 jil of BSA buffer containing 10,000 
cpm of 125I-hrIL-1 [3 was added to each tube; after vortexing the tubes were again 
incubated at room temperature overnight. On Day 3, 500 |xl of BSA buffer con­
taining 6% of PEG and 2.0% sheep anti-rabbit IgG were added. The tubes were 
vortexed and centrifuged at 1500# for 15 min in room temperature. The superna- 
tants were decanted, and the tubes were kept inverted and allowed to drain on 
absorbent paper for 15 min before being counted for radioactivity.
The mean 7  activity (cpm) of duplicate or triplicate standards was calculated 
and the counts of the NSB were subtracted. Counts of all standards and samples 
were expressed as the percentage of the standard containing no IL - ip  (zero stan­
dard = 100% binding). A standard curve was created by plotting the values (in 
percentage) of the standard samples against the concentration, on logit vs loga­
rithmic graph paper (Team Papers, Tamworth, NH) (Fig. 3). Detection limit of the
1000 10000
IL-1 G [pg/ml]
Fig .  3. Typical s tandard  curve  for IL-1J3 RIA. Precipitated activity (cpm) of  s tandards  was e x ­
pressed as the percentage o f  activity precipitated by anti IL - lp  in the absence  o f  cold I L - lp  (zero 
s tandard  =  100% binding). A s tandard  curve was created  by plotting the values in the percentage  o f  
the s tandard  sam ples  against the known concentra t ion  on logit vs logarithmic graph paper.  The  logit 
function (logit b = In 1/7/ ( 100-/;)]) t ransform s a sigmoid to a linear-binding curve .  The  horizontal line 
indicates the detect ion  limit which was set at 95% of  zero s tandard .
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assay was set at binding ^95%  of zero standard. In one series of 13 consecutive 
R IA ’s the median detection limit was 115 pg/ml (range 35 to 250 pg/ml).
The RIA for h rIL -ip  did not cross-react with the human recombinant proteins 
at the indicated concentrations: 10 or 100 ng/ml IL - la  (kindly provided by Dr. 
Alan Shaw, Glaxo Institute of Molecular Biology), 100 or 1000 U/ml interleukin-2 
(spec act 106 U/mg, Cetus Corp.), 10 or 100 ng/ml T N F (kindly provided by 
Biogen, Cambridge, MA), 100 or 1000 U/ml interferon-a (spec act 107 U/mg, 
Schering Corp., Kenilworth, NJ), 100 or 1000 U/ml of interferon-7 (spec act 107 
U/mg, Schering Corp.), 0.5 or 5 ng/ml granulocyte monocyte colony-stimulating 
factor (Genetics Institute, Cambridge, MA), and 50 or 100 ng/ml of complement 
component C5a des arg (kindly provided by Dr. K. B. Yancey, Uniformed Ser­
vices University of the Health Sciences, Bethesda, MD).
Radioimmunoassays for human IL - la  (33) and T N F (34) were performed as 
described.
In Vitro Mononuclear Cell Stimulation
Venous blood was drawn into heparinized (20 U/ml) syringes. At the same time, 
a sample of unheparinized blood was taken in order to prepare heat-inactivated 
(56°C, 40 min) serum. The MNC fraction was obtained by density centrifugation 
of diluted heparinized blood (one part blood to two parts pyrogen-free normal 
saline) over Ficoll-Hypaque (spec wt 1.077 g/ml). This was prepared by dissolving 
Ficoll (Type 400, Sigma) with Hypaque (Hypaque-M, 90%; W inthrop-Breon 
Lab., New York, NY) in ultrafiltered water. MNC were washed twice in 0.15 M  
NaCl, slides were prepared by cytocentrifugation, and 100 cell differential counts 
were performed by light microscopy on Wright stained slides. RPMI 1640 culture 
medium (Whittaker M. A. Bioproducts, Walkersville, MD), supplemented with 2 
mM  L-glutamine, 100 U/ml penicillin, and 100 fjig/ml streptomycin, was subjected 
to ultrafiltration in order to remove endotoxins as previously described (35). MNC 
were suspended at 5 x 106 MNC/'ml in RPMI with 2% heat-inactivated autologous 
serum and 100 fxl were aliquoted in 96-well flat-bottom microtiter plates. An equal 
volume of either RPMI or RPMI containing various stimulants was added. The 
cells were stimulated with endotoxin (lipopolysaccharide Escherichia coli 055:B5, 
Sigma L-2880; aliquots stored at 1 ^ig/ml stock concentration) at 1 and 10 ng/ml; 
phytohemagglutinin (PHA-P; Difco, Detroit, MI; aliquots stored at 600 |JLg/ml) at
3 |xg/ml; or heat-killed, opsonized (with 2.5% fresh autologous serum) Staphy­
lococcus epidermidis at 20 bacteria:MNC. Each stimulus was added to triplicate 
wells. After 24 hr at 37°C in 5% CO: , the microtiter plates were frozen at -70°C  
until the end of the study. At that time plates were thawed and exposed to two 
more freeze-thaw cycles, simultaneously for all plates from each donor, to com­
plete cell lysis. The contents of triplicate wells, consisting of cell lysates and 
supernatants, were pooled and refrozen for IL-1 and T N F determinations. Alter­
natively, the cells were treated with the detergent 3-[(3-cholamidopropyl)- 
dimethylammonio]-l-propanesulfonate (CHAPS), aprotinin, or phenylmethylsul- 
fonyl fluoride (PMSF; all from Sigma) during the freeze-thaw cycles.
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RESULTS
Solubilization o f  /L - /p
We examined different procedures to prepare total (i.e., secreted plus cell- 
associated) immunoreactive IL - ip  from MNC at the termination of the incubation 
period. Commonly, MNC cultures are lysed by freeze-thawing and the lysates are 
directly assayed in the R1A. Several issues regarding this procedure were ad­
dressed: (i) Does removal of cell debris from the lysates by short, high-speed 
centrifugation affect the recovery of IL - ip?  (ii) Can more 1L- 1 p be solubilized by 
adding the detergent CHAPS to the lysates as compared to repeated freeze- 
thawing? and (iii) Does addition of the protease inhibitors aprotinin and PMSF 
increase recovery of IL - lp  by reducing proteolytic degradation?
MNC from three healthy donors were stimulated in two microtiter plates as 
described above. The cells were stimulated identically with 10 ng/ml of endotoxin. 
After 24 hr the incubation was stopped by freezing at -  70°C. Thereafter the wells 
were treated according to three different protocols.
(i) “ F T ” (freeze-thaw): The plate was subjected to two more cycles of freezing 
(60 min, -70°C ) and thawing (60 min; 37°C); after the last thaw the wells were 
mixed and the content of two wells (200 jxl) was transferred into a 1.5-ml mi- 
crofuge tube; one of the tubes was kept for direct assay by RIA; the other tube 
was spun in a microcentrifuge (13,000,? 5 min) and 180 |xl of the supernatant was 
transferred into a new tube for later assay by RIA.
(ii) “ FT/A P" (freeze-thaw, aprotinin, PMSF): After thawing, 22 \x\ of aprotinin 
(5 trypsin inhibitory units [TIU]/ml) and PMSF (10 mM) in RPMI was added to 
each well and the plate was subjected to the same procedures described for FT 
above;
(iii) “ C H /A P" (CHAPS, aprotinin, PMSF): After thawing the plate was placed 
on ice; 22 | J  of CHAPS (90 mM), aprotinin (5 TIU/ml), and PMSF (10 mM) in 
RPMI were added to each well; after 30-min incubation on ice 200 \x\ from each 
of two wells was transferred into one microfuge tube containing 200 (jlI of ice-cold 
BSA buffer. From one of the tubes cell debris was removed as for FT wells.
Triplicate wells were prepared by each of the three protocols for each donor. 
Samples were measured for immunoreactive IL -ip  in duplicate by RIA. Prepa­
ration of IL-1 standards in medium containing the same final concentrations of 
CHAPS (9 mM), PMSF (0.5 mM), and aprotinin (0.5 TIU/ml) as the samples did 
not significantly change the standard curve of the RIA (data not shown).
As shown in Fig. 4, for all three donors maximal immunoreactive IL - lp  was 
recovered when the MNC samples were subjected to three freeze-thaw cycles 
without removing cell debris. Removing cell debris reduced measurable IL - ip ,  
probably due to IL - lp  associated with fragments of cell membranes. Even though 
this membrane-associated IL -1 p is not solubilized, its epitopes probably bind with 
the polyclonal antiserum in the RIA. In the presence of protease inhibitors, im­
proved recovery of IL -1 p was not observed. In fact, the presence of these inhib­
itors reduced the amount of measurable IL -1 p in the samples where cell debris
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Fig .  4. R ecovery  o f  im m unoreac tive  IL-1 (3 for different p repara tions  o f  m ononuc lea r  cells after 
incubation. M N C  were stimulated with 10 ng/ml endotoxin  for 24 hr. At the end o f  the incubation 
period cells were prepared  according to different protocols  (for details,  see text): “ F T " ,  three f re e z e -  
thaw  cycles;  “ F T /A P " ,  addition o f  aprotinin and P M S F  after first o f  three f reeze - th aw  cycles;  “ C H / 
A P “ , addition o f  the detergent C H A P S ,  aprotinin, and PM SF. All samples were assayed  directly or  
af ter  rem oving cell debris  by centrifugation (13,000#, 5 min). Bars indicate mean ±  SEM  for three 
donors  exp ressed  as the percentage  of  maximal recovery  (FT  preparation).
had not been removed. This may indicate that the action of proteases actually 
increases the recovery of immunoreactive IL -1 (3 from samples which contain cell 
debris. It has previously been shown that trypsin can liberate IL-1 from mem­
branes (36). Surprisingly, the lowest recovery occurred with the addition of 
CHAPS detergent. This agent has been shown to liberate IL-1 from membranes 
(36). However, it may also lead to partial denaturation of the IL-1 (3 molecule as 
indicated by reduced bioactivity (37). The low values measured in the presence of 
CHAPS are not due to interference of the detergent with the antigen-antibody 
binding in the R1A since we did not observe a shift of the standard curve in the 
presence of 9 mM  CHAPS. In our subsequent studies, the protocol using three 
freeze-thaw cycles was employed for preparing MNC for total IL-1 [3 measure­
ment.
I nte r as say R ep roduciblI i ty
To determine interassay reproducibility, MNC from one donor were stimulated 
with endotoxin, PHA, or heat-killed S. epidermidis at several time points over a 
period of 6 months. At the end of 6 months, samples were aliquoted in duplicate 
tubes and stored at -70°C . IL - ip  was measured by RIA at two time periods: 1 or
4 months later. In the first assay, samples for all stimulation conditions were 
assayed in a single RIA. In the second assay, 3 months later, the samples were 
assayed in four different RIAs, separate for samples from each stimulation con­
dition. Each of these latter RIAs were compared to the results of the RIA per­
formed during the first month (Fig. 5) and a correlation coefficient was calculated 
by the least squares method (Cricket Graph 1.0, Cricket Software, Philadelphia, 
PA). The individual correlation coefficients between the first RIA and the four 
RIAs 3 months later are depicted in Fig. 5. The correlation coefficient for the 
pooled data pairs is R = 0.97. The average ratio of concentrations measured at 
Month 4 vs Month 1 was 0.94. Thus, the RIA yields highly reproducible results.
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Month 4: IL-1 3 [ng/ml]
Fig. 5. In te rassay  reproducibil i ty  and stability o f  natural IL-1(3 at - 7 0 ° C .  Thirty-six  sam ples  of  
M N C  (stimulated with four different stimuli at different times) from one d on o r  were  s tored  in duplicate  
tubes  at - 7 0 ° C  and assayed  at two different occas ions  3 m onths  apart .  Result o f  assay  during M onth  
I versus  result o f  four different assays  (one for each stimulus) during Month 4 is plotted for each 
sample. The  correlat ion coefficients be tw een  the assay  during Month 1 and the individual assays  
during M onth 4 are indicated. The com bined  correlation coefficient for all da ta  points is 0.97. The 
slope o f  the diagonal line indicates the mean ratio (0.94) o f  m easu rem en t  during M onth 4 o v e r  m ea ­
surem ent  during Month 1.
The data also demonstrate that samples can be stored at -7 0 °C  for at least 3 
months without appreciable loss of recovery.
Intrasubject Consistency
To assess intrasubject consistency, MNC from six healthy donors were stim­
ulated on 3 different days, each 2 to 3 days apart. Four different stimulation 
conditions were used (endotoxin, 10 and 1 ng/ml; PHA, 30 |JLg/ml; and heat-killed 
S. epidermidis). lmmunoreactive IL-1 (3, IL - la ,  and T N F were measured. Undi­
luted samples from unstimulated (control) MNC consistently contained cytokines 
below the detection limit of 115 pg/ml (IL-ip), 40 pg/ml (IL -la ) ,  and 20 pg/ml 
(TNF). The levels of IL-1 (3 for the six different donors are depicted in Fig. 6 . The 
levels are consistent for the repeated determinations on different days; the aver­
age (n = 24) coefficient of variation (SD/mean) is 29%. Production of IL - la  and 
T N F  was equally consistent (individual data not shown). The average coefficient 
of variation was 20% for T N F and 30% for IL - la .  The average proportion of 
monocytes in the MNC population (after Ficoll-Hypaque separation), assessed by 
light microscopy, was 21%. We found no correlation between the proportion of 
monocytes in the MNC population and the level of IL-1 p produced. This supports 
the recent findings that in addition to monocytes, natural killer cells (38, 39), and 
B cells (40) produce IL-1 and T N F (41) in response to endotoxin or PHA.
MNC from nine donors were again stimulated 26 weeks later, again on 3 dif­
ferent days, 2 to 3 days apart. Concentrations of IL - lp  induced by 1 ng/ml en­
dotoxin are plotted in Fig. 7 (mean ± SEM for determination on 3 different days). 
Six of the donors remained in the same range of low, intermediate, or high pro-
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Fig .  6 . In trasubject  consis tency  for in vitro p roduction  o f  IL - ip .  M N C  from six healthy donors  
were  s t imulated on 3 different days ,  2 to 3 days apart .  Four  different stimulation condit ions were  used:
1 ng/ml o f  endotox in  (ET  1), 10 ng/ml o f  endotox in  (ET  10), 3 p-g/ml o f  PH A , and heat-killed S. 
epidermidis (20 organ ism s/M N C).  Total ,  i.e., cell-associated plus secre ted ,  IL - lp  was m easured  by 
RIA. * D enotes  sample not tested for donor  4.
ducer, respectively, after this time period. MNC from donors 4 and 9 produced 
more IL - lp  at the end of the study period, while the cells from donor 6 showed a 
decreased response when compared to the baseline determination.
Relative Amounts o f  Cytokines
Figure 8 compares induction of cytokine production by the different stimuli 
employed. Each value represent the mean of 18 measurements (six donors on 3 
different days each). There appears to be a strikingly discrete pattern for each 
stimulation condition. Endotoxin induces twofold more IL - la  than IL -ip  or TN F, 
which are produced in equal amounts. When PHA is used as a stimulus, concen­
trations of IL - la  and T N F are comparable to endotoxin stimulation, while only 
half as much IL -ip  is produced. The phagocytic stimulus heat-killed S. epider­
midis induces markedly higher levels of total cytokine, with a fourfold prevalence 
of both IL -ip  and T N F over IL -la .
Donor 2
Donor 6
ET 1 ET 10 PHA S. epid.
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#5 #7 #8 #2 #10 #3 #4 #9 #6
Week 1 versus Week 26
Fig. 7. Long-term  variation o f  IL - lp  production .  M N C  from nine donors  (No. 2 to No. 10) were 
st imulated with 1 ng/ml o f  endotoxin  on 3 different days ,  2 to 3 days apar t ,  and again on 3 different days  
25 weeks later. Total ,  i .e.,  cell-associated plus secre ted ,  IL-1(3 was m easured  by R1A. Bars indicate 
m ean ±  SEM  o f  de te rm ina t ions  on three different days.
DISCUSSION
The main goal of the present study was to define experimental conditions for 
reproducible in vitro cytokine production. A prerequisite for defined stimulation 
of MNC are endotoxin-free culture conditions. Commercially prepared density 
gradient media may contain appreciable amounts of endotoxin. We therefore 
prepare powdered Ficoll and clinical grade Hypaque in ultrafiltrated water to use 
for density separation of MNC. We also routinely subject commercial culture 
media through an ultrafiltration unit (U 2000, Gambro, Hechingen, FRG). This 
removes endotoxin both by molecular weight exclusion (cut-off 30,000 D) and by 
adsorption to the large polyamide surface (35). Since fetal calf serum is also a 
possible source of endotoxin we use heat-inactivated autologous or human AB 
serum as a serum supplement. These measures enable us to culture MNC without 
significant activation of the cells. Cytokine production in control wells without 
addition of a stimulus was consistently below the detection limit of the RIAs.
CDc
<Dc
o>O
40 "
30 -
20 -
10 -
0
endotoxin PHA S. epidermidis
Fig. 8 . Relative am oun ts  o f  IL-l(3, I L - l a ,  and T N F  in response  to different stimuli. M N C  were 
st imulated with endotoxin  10 ng/ml. PHA 3 jig/ml. or  heat-killed .S', epidermidis (20 o rgan ism s/M N C ) 
for 24 hr and total, i.e.,  cell-associated plus secre ted ,  cytokine production  was assayed  by R1A. Each 
value rep resen ts  the mean o f  18 m easurem en ts  (six donors  on 3 different days each).
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Several studies have reported constituitive in vitro production of cytokines by 
monocytes of patients and healthy individuals. Particular care must be taken to 
exclude inadvertent endotoxin contamination from cell separation or culture me­
dia as a possible source of such “ spontaneous" production. While we observed no 
spontaneous production we were able to induce high levels of cytokine ( 1-10 
ng/ml) by minimal concentrations of endotoxin (1 ng/ml).
With the availability of RIAs, the optimal conditions for the preparing of MNC 
cultures for cytokine measurements have to be defined. Secretion of IL-1 may be 
regulated independently from synthesis (42) and selectively inhibited (43). We 
thus believe that total (i.e., cell-associated plus secreted) IL-1 is required to assess 
the synthetic capacity of a cell population. This is particularly important since 
membrane-bound IL-1 (3 is biologically active in a variety of immunological and 
inflammatory models.
IL-1 can be solubilized from intact cells by mechanical lysis through freeze- 
thawing, sonication (42), or homogenizing (36) or by use of detergents such as 
CHAPS (36), Triton X, or digitonin (44). These different methods have not been 
compared in preparing samples for measurement by RIA. We achieved greater 
recovery of immunoreactive IL -ip  by lysis through repeated freeze-thawing than 
by solubilizing using CHAPS. The reduced levels of IL -ip  we observed using 
CHAPS may be due to partial denaturation of the IL-1 (3 molecule as indicated by 
reduced bioactivity (42). Furthermore, the addition of the protease inhibitors 
aprotinin and PMSF did not improve recovery of IL-1 p. Removing cell debris 
from the lysates by high-speed centrifugation decreased recovery of IL-1 p.
Using the conditions that achieve maximal recovery of IL - ip ,  we examined the 
reproducibility of in vitro cytokine production for individual subjects on different 
days, 1 or 2 days apart. We found consistently reproducible concentrations of 
IL - lp ,  IL - la ,  and TNF. The average coefficient of variation for repeated mea­
surements was 29% for IL - ip ,  30% for IL - la ,  and 20% for TNF. These values 
comprise the cumulative variation from two sources: first, the temporal variation 
due to measurement on different days; second, the variation due to measurement 
error in repeated measurements. From the format of the study we cannot dissect 
what relative share of the variability stems from either of these two sources. 
However, we can conclude that neither of the two sources of variation amounts 
to more than the observed level. This implies that in vitro cytokine production is 
a biological parameter that is both technically reproducible and stable within one 
subject over the time span of several days. Technical reproducibility and temporal 
stability are required to investigate altered cytokine production in different dis­
ease states. We found reproducible levels of induced cytokines for separate stim­
ulations as far as 6 months apart (Fig. 7). This indicates the preserved potency of 
the stimuli used when stored in sufficiently high concentrations at — 70°C.
In this study we show that each of the cytokines are produced at different levels 
in response to different stimuli. For the soluble stimuli, endotoxin and PHA, a 
roughly similar pattern was found (Fig. 8). Surprisingly, using these stimuli, twice 
as much IL - la  as IL -1 p was produced despite the well-established abundance 
of IL -ip  mRNA over that of IL - la  mRNA in MNC (45, 46). Heat-killed S. cpi- 
dermidis as a phagocytic stimulus induced a distinctly different pattern of cyto­
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kine production. IL - lp  and T N F production were fivefold higher than IL - la  
production. This finding supports the concept of differential cytokine gene ex­
pression in MNC in response to different stimuli. It has been previously reported 
that relatively more IL -1 remains cell associated upon stimulation with endotoxin 
as compared to a phagocytic stimulus (42). On the other hand, the cell-associated 
compartment appears to be mainly IL - la ,  while secreted IL-1 is mostly the IL -lp  
form as determined by physicochemical characterization (37) and by immunore- 
activity (33, 39, 47).
For different stimulation conditions, IL - ip  and T N F production thus appears to 
be correlated while IL - la  production changes independently. This is in contrast to 
the intersubject correlation of cytokines: in another study (48) we have examined 
in vitro IL - lp ,  IL - la ,  and T N F  production in a large cohort of normal volunteers. 
From individual to individual IL - ip  and IL - la  production appeared to be linked, 
whereas T N F  production showed no correlation with either IL - ip  or IL - la .
In summary, we observed a parallel variation of IL - ip  and T N F  production for 
different stimuli, and a parallel variation of IL - ip  and IL - la  production for dif­
ferent individuals. The gene for IL - ip  is localized on chromosome 2 of the human 
genome (49); in the murine genome the genes for IL - ip  and IL - la  are tightly 
linked on chromosome 2 (50). Correlation of cytokine production suggests depen­
dent regulation of the respective genes. Whether this linkage of regulation occurs 
at the transcriptional or the translational level remains to be investigated.
The finding of consistently high and consistently low cytokine production for 
some subjects supports the concept of high and low responders to particular 
stimulants and the concept of genetic factors controlling cytokine gene expres­
sion. Recently, the human T N F  gene has been located in the HLA region on the 
short arm of chromosome 6 , probably closely linked to the HLA-B locus (51). 
This chromosomal location raises the possibility of a linkage disequilibrium be­
tween different HLA-haplotypes and polymorphisms of the T N F  gene. One can 
speculate on high and low T N F  producer phenotypes as a possible link between 
HLA alleles and some HLA haplotype-associated diseases, such as ankylosing 
spondylitis and insulin-dependent diabetes mellitus (52).
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